F Montes de Jesus1, D Dierickx2, V Vergote2, W Noordzij3, R A J O Dierckx3, C M Deroose4, A W J M Glaudemans3, O Gheysens5, T C Kwee6. 1. Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9700 RB, Groningen, The Netherlands. f.m.montes.de.jesus@umcg.nl. 2. Department of Hematology, University Hospitals Leuven, Leuven, Belgium. 3. Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9700 RB, Groningen, The Netherlands. 4. Department of Nuclear Medicine, University Hospitals Leuven, Leuven, Belgium. 5. Department of Nuclear Medicine, Cliniques Universitaires Saint-Luc, Brussels, Belgium. 6. Department of Radiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Abstract
BACKGROUND: Post-transplant lymphoproliferative disorders (PTLDs) are a spectrum of hematological malignancies occurring after solid organ and hematopoietic stem cell transplantation. [18F]FDG PET/CT is routinely performed at PTLD diagnosis, allowing for both staging of the disease and quantification of volumetric parameters, such as whole-body metabolic tumor volume (MTV) and total lesion glycolysis (TLG). In this retrospective study, we aimed to determine the prognostic value of MTV and TLG in PTLD patients, together with other variables of interest, such as the International Prognostic Index (IPI), organ transplant type, EBV tumor status, time after transplant, albumin levels and PTLD morphology. RESULTS: A total of 88 patients were included. The 1-, 3-, 5- year overall survival rates were 67%, 58% and 43% respectively. Multivariable analysis indicated that a high IPI (HR: 1.56, 95% CI: 1.13-2.16) and an EBV-negative tumor (HR: 2.71, 95% CI: 1.38-5.32) were associated with poor overall survival. Patients with a kidney transplant had a longer overall survival than any other organ recipients (HR: 0.38 95% CI: 0.16-0.89). IPI was found to be the best predicting parameter of overall survival in our cohort. Whole-body MTV, TLG, time after transplant, hypoalbuminemia and PTLD morphology were not associated with overall survival. CONCLUSION: [18F]FDG PET/CT whole-body volumetric quantitative parameters were not predictive of overall survival in PTLD. In our cohort, high IPI and an EBV-negative tumor were found to predictors of worse overall survival while kidney transplant patients had a longer overall survival compared to other organ transplant recipients.
BACKGROUND: Post-transplant lymphoproliferative disorders (PTLDs) are a spectrum of hematological malignancies occurring after solid organ and hematopoietic stem cell transplantation. [18F]FDG PET/CT is routinely performed at PTLD diagnosis, allowing for both staging of the disease and quantification of volumetric parameters, such as whole-body metabolic tumor volume (MTV) and total lesion glycolysis (TLG). In this retrospective study, we aimed to determine the prognostic value of MTV and TLG in PTLDpatients, together with other variables of interest, such as the International Prognostic Index (IPI), organ transplant type, EBVtumor status, time after transplant, albumin levels and PTLD morphology. RESULTS: A total of 88 patients were included. The 1-, 3-, 5- year overall survival rates were 67%, 58% and 43% respectively. Multivariable analysis indicated that a high IPI (HR: 1.56, 95% CI: 1.13-2.16) and an EBV-negative tumor (HR: 2.71, 95% CI: 1.38-5.32) were associated with poor overall survival. Patients with a kidney transplant had a longer overall survival than any other organ recipients (HR: 0.38 95% CI: 0.16-0.89). IPI was found to be the best predicting parameter of overall survival in our cohort. Whole-body MTV, TLG, time after transplant, hypoalbuminemia and PTLD morphology were not associated with overall survival. CONCLUSION: [18F]FDG PET/CT whole-body volumetric quantitative parameters were not predictive of overall survival in PTLD. In our cohort, high IPI and an EBV-negative tumor were found to predictors of worse overall survival while kidney transplant patients had a longer overall survival compared to other organ transplant recipients.
Authors: Ronald Boellaard; Wim J G Oyen; Corneline J Hoekstra; Otto S Hoekstra; Eric P Visser; Antoon T Willemsen; Bertjan Arends; Fred J Verzijlbergen; Josee Zijlstra; Anne M Paans; Emile F I Comans; Jan Pruim Journal: Eur J Nucl Med Mol Imaging Date: 2008-08-15 Impact factor: 9.236
Authors: Matthew J Hourigan; James Doecke; Peter N Mollee; Devinder S Gill; Debra Norris; David W Johnson; Maher K Gandhi Journal: Br J Haematol Date: 2008-04-13 Impact factor: 6.998
Authors: Irene M Ghobrial; Thomas M Habermann; Matthew J Maurer; Susan M Geyer; Kay M Ristow; Timothy S Larson; Randall C Walker; Stephen M Ansell; William R Macon; Gregory G Gores; Mark D Stegall; Christopher G McGregor Journal: J Clin Oncol Date: 2005-09-26 Impact factor: 44.544
Authors: Ralf U Trappe; Daan Dierickx; Heiner Zimmermann; Franck Morschhauser; Peter Mollee; Jan M Zaucha; Martin H Dreyling; Ulrich Dührsen; Petra Reinke; Gregor Verhoef; Marion Subklewe; Andreas Hüttmann; Thomas Tousseyn; Gilles Salles; Volker Kliem; Ingeborg A Hauser; Corrado Tarella; Eric Van Den Neste; Olivier Gheysens; Ioannis Anagnostopoulos; Veronique Leblond; Hanno Riess; Sylvain Choquet Journal: J Clin Oncol Date: 2016-12-19 Impact factor: 44.544
Authors: S Caillard; F X Lamy; C Quelen; J Dantal; Y Lebranchu; P Lang; M Velten; B Moulin Journal: Am J Transplant Date: 2012-01-06 Impact factor: 8.086
Authors: Nicolaas A Bakker; Gustaaf W van Imhoff; Erik A M Verschuuren; Willem J van Son; Jaap J Homan van der Heide; Nic J G M Veeger; Philip M Kluin; Hanneke C Kluin-Nelemans Journal: Clin Transplant Date: 2005-06 Impact factor: 2.863
Authors: Britta Maecker; Thomas Jack; Martin Zimmermann; Hashim Abdul-Khaliq; Martin Burdelski; Alexandra Fuchs; Peter Hoyer; Sabine Koepf; Ulrike Kraemer; Guido F Laube; Dirk E Müller-Wiefel; Heinrich Netz; Martin Pohl; Burkhard Toenshoff; Hans-Joachim Wagner; Michael Wallot; Karl Welte; Michael Melter; Gisela Offner; Christoph Klein Journal: J Clin Oncol Date: 2007-11-01 Impact factor: 44.544